Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081975 | 0.90 | LGALS9 (0.43) | KMT2AMAPTNPSR1GAABCHE | |
| SCHEMBL475965 | 0.90 | LGALS9 (0.43) | KMT2AMAPTNPSR1GAABCHE | |
| SCHEMBL19326490 | 0.90 | LGALS9 (0.43) | KMT2AMAPTNPSR1GAABCHE | |
| SCHEMBL12355571 | 0.88 | KMT2A (0.39) | KMT2AMAPTNPSR1GAALMNA | |
| SCHEMBL10017434 | 0.88 | KMT2A (0.39) | KMT2AMAPTNPSR1GAALMNA | |
| SCHEMBL14473769 | 0.88 | ALDH1A1 (0.47) | KMT2AMAPTNPSR1GAALMNA | |
| SCHEMBL12481647 | 0.88 | ALDH1A1 (0.47) | KMT2AMAPTNPSR1GAALMNA | |
| SCHEMBL475953 | 0.88 | ALDH1A1 (0.47) | KMT2AMAPTNPSR1GAALMNA | |
| SCHEMBL13151599 | 0.88 | ALDH1A1 (0.47) | KMT2AMAPTNPSR1GAALMNA | |
| SCHEMBL15117573 | 0.88 | ALDH1A1 (0.47) | KMT2AMAPTNPSR1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9376410-B2 | (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2016-06-28 | — | — | US | disclosed |
| US-20150284351-A1 | (2R)-2-DEOXY-2,2-DISUBSTITUTED-RIBONO-1,4-LACTONE AND PREPARATION METHOD AND USE THEREOF | TOPHARMAN SHANDONG CO., LTD. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284351-A1 | (2R)-2-DEOXY-2,2-DISUBSTITUTED-RIBONO-1,4-LACTONE AND PREPARATION METHOD AND USE THEREOF | RNASEL, RNASE1, RRM1 | KMT2A 2076/4885MAPT 4793/4885NPSR1 2514/4885 |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | PYGL, HAVCR2, PNP | KMT2A 2653/4885MAPT 2409/4885NPSR1 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.